| NCT07047144 | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy | RECRUITING | PHASE2 | 2025-09 | 2029-03 | 2028-11 |
| NCT06445075 | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | COMPLETED | PHASE2 | 2024-05-21 | 2025-06-17 | 2025-03-04 |
| NCT05626855 | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-04-17 | 2029-05-02 | 2026-11-01 |
| NCT05156320 | Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam | COMPLETED | PHASE3 | 2022-04-14 | 2024-12-18 | 2024-12-18 |
| NCT04291079 | SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) | COMPLETED | PHASE1 | 2020-04-23 | 2025-04-14 | 2025-04-14 |
| NCT03921528 | An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy | COMPLETED | PHASE2 | 2019-04-22 | 2024-02-28 | 2021-01-19 |